10 0例慢性乙型肝炎用重组干扰素αIb治疗 ,每支 30 0万IU ,隔日肌注 ,连续五个月为疗程。对照组用重组干扰素α Ⅱb治疗 ,其剂量、用法及疗程与治疗组相同。

结果治疗组与对照组比较 ,于疗程结束时 :HBeAg转阴率各为 47 0 %与 45 0 % ;HBV -DNA转阴率各为 5 3 0 %与 5 0 0 %。停药一年后随访时 :HBeAg持续转阴率各为 37 0 %与 36 0 % ;HBV -DNA持续转阴率各为 39 0 %与 37 0 %。二组间二项相比 ,无显著性差异 (P >0 0 5 )。说明赛若金与干扰能相比 ,具有疗效相仿 ,副反应低的优点。另对赛若金治疗血清肝纤维化指标的观察 ,于疗程结束时 ,其治前与治后比较HA各为 16 2 7± 6 8 5与 97 5± 43 3;Ⅳ c各为 79 8± 36 7与 5 6 5± 2 4 2。二项前后相比有显著差异 (P <0 0 5 ) ,提示赛若金有抗肝纤维化疗效。
patients with chronic hepatieis B were treated with recombinant interferon α Ⅰb 3 million IU with intramuscular in jecton every other day for five months The control group was treated with recombinant interferon α Ⅱb with same dose wsage and course At the end of treatment,serum HBeAg reansforming negative were 47 0% and 45 0%,respectively,HBV DNA transforming negative were 53 0% and 50 0%,respectively One year after the last administration,HBeAg transforming negative were 37 0% and 36 0% There is no statistical significance between the two groups(P>0 05) This shous that SINOGEN has the same therapeutn efficacy from Intron A but has Iower side effect than Intron A Meanuhile the index of hepatic fibrosis in serum were detected before and after treatment HA were 162 7±68 5 and 97 5±43 3,respectively(P<0 05)Ⅳ c were 79 8±36 7and56 5±24 2,respectively(P<0 05) It indicates that SINOGEN has efficacy of antihepatic fibrosis [WT5”HZ]
【Keyword】：WT5”BZ]Chronic hepatitis B;Recombinant interferon α Ⅰb;Recombinant interferon α Ⅱb;HBeAg;HBV DNA;HA;Ⅳ-c
慢性乙型肝炎易发展成肝硬化 ,甚至诱发成肝癌 ,国内外近年报告用重组干扰素α治疗慢性乙型肝炎有一定疗效 ,但多为α Ⅱｂ或α Ⅱａ。重组干扰素α Ⅰｂ(赛若金 )为我国自己研制的基因工程药物。我院自 1996年 4月至 1999年 10月应用该药治疗慢性乙型肝炎 ,其中五个月为疗程者 10 0例 ,定期检查和持续随访观察至停药后一年。另将同期应用重组干扰素α Ⅱｂ(干扰能 )治疗慢性乙型肝炎 10 0例设为对照组 ,以比较两组血清乙肝病毒标志转换和用药后不良反应的情况。此外对赛若金治疗肝纤维化指标ＨＡ、Ⅳ ｃ于疗程结束时进行比较 ,结果观察到治疗效果好。